TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23052798

Group type: EXPERIMENTAL
Intervention: Dunhill operation (DO)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bilateral subtotal resection (BST)
Number of subjects: 200
Study: 21820543

Group type: EXPERIMENTAL
Intervention: Step It exercise programme plus standard care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study: 19474735

Group type: EXPERIMENTAL
Intervention: CAMP test for pitch direction discrimination
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CAMP test for melody recognition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CAMP test for timbre recognition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest reliability for pitch
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest reliability for melody
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest reliability for timbre
Number of subjects: 42
Study: 17644623

Group type: EXPERIMENTAL
Intervention: Peak exercise capacity (measured in METs)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Waist circumference and BMI
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: A1C levels
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Hypertension and diabetes medications (in women)
Number of subjects: 5145
Study: 16824835

Group type: COMPARATOR
Intervention: Advanced stethoscope
Number of subjects: 72

Group type: COMPARATOR
Intervention: Simple stethoscope
Number of subjects: 72

Group type: COMPARATOR
Intervention: Teaching course
Number of subjects: 72

Group type: COMPARATOR
Intervention: No teaching course
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Teaching for aortic stenosis
Number of subjects: 72

Group type: COMPARATOR
Intervention: No teaching for aortic stenosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Teaching for ventricular septum defect
Number of subjects: 72

Group type: COMPARATOR
Intervention: No teaching for ventricular septum defect
Number of subjects: 72
Study: 14533127

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study: 10979113

Group type: EXPERIMENTAL
Intervention: Niacin (3000 mg/d)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 8799880

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (baseline)
Number of subjects: 10
Study: 1621412

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 0.3 x 10(4) c.f.u.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 1.6 x 10(5) c.f.u.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 1.9 x 10(6) c.f.u.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vibrio cholerae El Tor Inaba strain N16961 inoculation of 2.0 x 10(7) c.f.u.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Estimated inoculation of 1.3 x 10(7) c.f.u. of V. cholerae
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of groups inoculated with different dosages
Number of subjects: 26
Study: 6322709

Group type: EXPERIMENTAL
Intervention: Cimetidine, 1,200 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine, 2,400 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study: 30875247

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg oral, thrice weekly for 48 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 28025189

Group type: EXPERIMENTAL
Intervention: Cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n=120)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Sham procedure (n=151)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Cardiopoietic cells in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Cardiopoietic cells (n=120)
Number of subjects: 271
Study: 26292180

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) 1.8 g/day combined with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (no TGP) with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Number of subjects: 268
Study: 23599410

Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded polysulfone dialyzers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polysulfone control group
Number of subjects: 0
Study: 21535424

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for first-episode psychosis participants (n = 25)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (CBT) for stable psychosis patients (n = 15)
Number of subjects: 40
Study: 18477407

Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Conventional PT exercise
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 17123219

Group type: EXPERIMENTAL
Intervention: Specific aftercare measures after inpatient therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific aftercare measures)
Number of subjects: 0
Study: 15597799

Group type: EXPERIMENTAL
Intervention: Activated protein C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11392345

Group type: EXPERIMENTAL
Intervention: Prepubertal major depressive disorder (PMDD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal comparison (NC) group
Number of subjects: 100
Study: 9427854

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 31

Group type: COMPARATOR
Intervention: CYA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both FK506 and CYA
Number of subjects: 31
Study: 8387177

Group type: COMPARATOR
Intervention: Mitomycin and cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitomycin, vindesine, and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant MVP (mitomycin, vindesine/vinblastine, higher-dose cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone preceding mitomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone premedication
Number of subjects: 0
Study: 3500381

Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (5.1 mg/kg/day for 9 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thrice daily tobramycin (5.1 mg/kg/day for 9 days)
Number of subjects: 20
Study: 30977094

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 105
Study: 29095725

Group type: EXPERIMENTAL
Intervention: Guided Internet-Based Cognitive Behavior Therapy (iCBT) for tinnitus over 8 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Weekly monitoring (control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Guided iCBT
Number of subjects: 146
Study: 26849141

Group type: EXPERIMENTAL
Intervention: Trinity Evolution (TE) with PEEK interbody spacer
Number of subjects: 31
Study: 24521153

Group type: EXPERIMENTAL
Intervention: Lifestyle coaching approaches (problem-solving, self-monitoring skills)
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Lifestyle coaching approaches (problem-solving)
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Lifestyle coaching approaches (more costly approaches)
Number of subjects: 1076
Study: 24349492

Group type: EXPERIMENTAL
Intervention: Patients with RBD
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with RBD (daytime consolidation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with RBD (sleep talking)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with RBD (dementia)
Number of subjects: 18
Study: 20962352

Group type: EXPERIMENTAL
Intervention: Canaloplasty (360° catheterisation of Schlemm's canal with a flexible microcatheter and tensioning 10‐0 polypropylene suture)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Canaloplasty
Number of subjects: 60
Study: 18412805

Group type: EXPERIMENTAL
Intervention: Iontophoresis of botulinum toxin type A applied to the dominant (right) hand
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline applied to the non-dominant (left) hand (Control)
Number of subjects: 8
Study: 16796458

Group type: EXPERIMENTAL
Intervention: Simultaneous postoperative teleradiotherapy and radioimmunotherapy (TRT + RIT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Teleradiotherapy alone (TRT)
Number of subjects: 18
Study: 12641503

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU) and calcium citrate (800 mg) daily (group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (25 mg b.d., group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (1 mg every 3 months, group C)
Number of subjects: 84
Study: 10890672

Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen (cyclooxygenase inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8615317

Group type: EXPERIMENTAL
Intervention: Anodal monophasic shock
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cathodal biphasic shock
Number of subjects: 20
Study: 1479464

Group type: EXPERIMENTAL
Intervention: Aquavene test catheter
Number of subjects: 63

Group type: COMPARATOR
Intervention: Teflon control catheter
Number of subjects: 63
Study: 6589106

Group type: EXPERIMENTAL
Intervention: Powered rotary toothbrush
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional hand brush
Number of subjects: 10
Study: 30780196

Group type: EXPERIMENTAL
Intervention: Vortioxetine combined with cognitive behaviour intervention therapy
Number of subjects: 82
Study: 28278599

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of CBT and sertraline
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study: 27419388

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise program (3 times weekly for 4 months on a bicycle ergometer at 60-70% heart rate reserve)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study: 25591513

Group type: EXPERIMENTAL
Intervention: Ceraxon (citicoline)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Management rules
Number of subjects: 120
Study: 22682213

Group type: EXPERIMENTAL
Intervention: Treatment received during the trial
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intervention adherence
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability of assessments
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Blinding of assessments
Number of subjects: 100
Study: 19733016

Group type: EXPERIMENTAL
Intervention: Postoperative continuous accelerated irradiation (p‐CAIR) therapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Postoperative conventional fractionation (p‐CF) therapy
Number of subjects: 148
Study: 17965037

Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol per day
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol per day
Number of subjects: 218

Group type: COMPARATOR
Intervention: 0 IU cholecalciferol per day
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 218
Study: 16162258

Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Migraine without aura (MoA)
Number of subjects: 169
Study: 15785177

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study: 11756862

Group type: EXPERIMENTAL
Intervention: Avonex treatment
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 383
Study: 9370894

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg elemental zinc per day)
Number of subjects: 111
Study: 1541219

Group type: EXPERIMENTAL
Intervention: Structured and standardized history taking and clinical examination (test phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (test phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline phase (clinical routine without additional intervention)
Number of subjects: 0
Study: 4043200

Group type: EXPERIMENTAL
Intervention: Piretanide treatment in patients with ascites
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Piretanide treatment after resolution of ascites
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Piretanide treatment in patients with diuretic resistant ascites
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Piretanide treatment in patients with gross ascites
Number of subjects: 7
Study: 29627695

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Resilience Training (MBRT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 61
Study: 27521483

Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dose radiation (LDR)
Number of subjects: 40
Study: 25471366

Group type: EXPERIMENTAL
Intervention: STI educational intervention (interactive training with basic STI knowledge, case scenarios, and poster distribution)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: STI educational intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study: 22845695

Group type: EXPERIMENTAL
Intervention: High cutoff (HCO) dialyzer (Gambro HCO1100)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional high-flux (HF) membrane
Number of subjects: 19
Study: 20627818

Group type: EXPERIMENTAL
Intervention: Placebo expectation condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No expectation condition
Number of subjects: 0
Study: 18708258

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 10
Study: 16122495

Group type: EXPERIMENTAL
Intervention: Novare Enclose proximal anastomotic device
Number of subjects: 50
Study: 12574564

Group type: EXPERIMENTAL
Intervention: NXY-059 915 mg over 1 hour followed by 420 mg/h for 71 hours
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NXY-059 1820 mg for 1 hour followed by 844 mg/h for 71 hours
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 12148471

Group type: EXPERIMENTAL
Intervention: Chlormadinone (2 mg/day for 5 days every month)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 35 micrograms plus desogestrel 150 mg (21 days every month)
Number of subjects: 32
Study: 10445964

Group type: EXPERIMENTAL
Intervention: Frontal Lobe Personality Scale (FLOPS) completed by family members of frontal lobe patients post-lesion
Number of subjects: 87
Study: 7845489

Group type: EXPERIMENTAL
Intervention: Expiratory chest roentgenograms
Number of subjects: 59

Group type: COMPARATOR
Intervention: Inspiratory chest roentgenograms
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control roentgenograms
Number of subjects: 59
Study: 2179857

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen, administered at 3, 4, and 6 months of age.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen.
Number of subjects: 0
Study: 7398002

Group type: EXPERIMENTAL
Intervention: Persantine plus aspirin (PR/A)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA)
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Placebo (PLBO)
Number of subjects: 2026
Study: 6339425

Group type: EXPERIMENTAL
Intervention: EMG-biofeedback relaxation training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Progressive relaxation training
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 24
Study: 31544719

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 202
Study: 29788903

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 27568513

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methadone treatment
Number of subjects: 0
Study: 24965385

Group type: EXPERIMENTAL
Intervention: Light mask that emits a dim green light worn every night for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study: 22037139

Group type: EXPERIMENTAL
Intervention: Daily tDCS sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Second daily tDCS sessions
Number of subjects: 12
Study: 20392706

Group type: EXPERIMENTAL
Intervention: Regular exercise (defined as exercise frequency equal to or more than once/week)
Number of subjects: 20920

Group type: COMPARATOR
Intervention: Exercise programmes offered at dialysis facilities
Number of subjects: 20920

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 20920

Group type: COMPARATOR
Intervention: Facilities with more regular exercisers
Number of subjects: 20920
Study: 18455192

Group type: EXPERIMENTAL
Intervention: tPA treatment
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Blood pressure declines >50 mmHg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Blood pressure declines >60 mmHg
Number of subjects: 551
Study: 16180627

Group type: EXPERIMENTAL
Intervention: Dopamine receptor agonist bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14516216

Group type: EXPERIMENTAL
Intervention: Older adults with connected components in memory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger adults under divided-attention conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults with unrelated attributes in memory
Number of subjects: 0
Study: 10787766

Group type: EXPERIMENTAL
Intervention: Behavioral and dietary intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All women (treatment and control)
Number of subjects: 80
Study: 9000327

Group type: EXPERIMENTAL
Intervention: Activator (mandibular advancement device)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Soft-palate lifter
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mouth-shield
Number of subjects: 15
Study: 1289589

Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) administered at a mean dose of 8.6 mg/kg in 3-4 divided doses for an average of 7 days.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) administered at doses of 4.0, 7.5, and 15.0 mg/kg to 9 children.
Number of subjects: 160
Study: 6362388

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 51
Study: 31218077

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate 240 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29888730

Group type: COMPARATOR
Intervention: intact teeth (control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ribbond in the occlusal surface + composite resin (Group 6)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: horizontal fiber post + composite resin (Group 7)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: unfilled MOD cavity (Group 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: MOD + composite resin (Group 3)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 10‐mm‐long fiber post + composite resin (Group 4)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 5‐mm‐long fiber post + composite resin (Group 5)
Number of subjects: 105
Study: 26133538

Group type: EXPERIMENTAL
Intervention: α-galactosidase (AG)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 25672160

Group type: EXPERIMENTAL
Intervention: Laser myringotomy (LM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Incisional myringotomy (classical myringotomy)
Number of subjects: 66
Study: 23213982

Group type: EXPERIMENTAL
Intervention: Multi-needling group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupotomy group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional acupuncture group
Number of subjects: 120
Study: 20933221

Group type: EXPERIMENTAL
Intervention: Feedback intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 18248689

Group type: EXPERIMENTAL
Intervention: Rivastigmine (1.5mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Meth (30mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23
Study: 15796146

Group type: EXPERIMENTAL
Intervention: Oral egg albumin-based protein supplement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional nutritional counseling (Control)
Number of subjects: 28
Study: 12188103

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine from Day 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment with rivastigmine
Number of subjects: 0